Translating scientific breakthroughs into first-in-class treatments
Novel insights into human biology define our development programs that target cancer
Pipeline Overview
Our oncology pipeline is focused on restoring and bolstering immune responses. Tizona is enrolling patients in two randomized arms within the ongoing Phase 1b clinical trial (NCT04485013) to evaluate either TTX-080 plus cetuximab and FOLFIRI or cetuximab and FOLFIRI alone in biomarker-defined metastatic colorectal cancer.
HLA-G Suppresses Both Adaptive & Innate Immune Activity
HLA-G is normally expressed at the maternal-fetal interface and certain sites of immune privilege. In cancer, its expression is used as an immune evasion strategy. HLA-G mediates its potent suppression through binding to receptors found on tumor infiltrating immune cells.
TTX-080 has the Potential to Enhance Anti-Tumor Responses
Publications
Society for Immunotherapy of Cancer Annual Meeting 2025
TTX-080, A First-in-Class HLA-G Specific Antagonist, Increases Distinct Innate and Adaptive Immune Cells in the Tumor Microenvironment and Periphery
American Society of Clinical Oncology 2024
Results from Ph1a/1b Analyses of TTX-080, a First-in-Class HLA-G Antagonist, in Combination with Cetuximab in Patients with Metastatic Colorectal Cancer and Head and Neck Squamous Cell Carcinoma